Integrating biosimilars into health systems pharmacies
By IHOC |
Biosimilars are reshaping the treatment landscape for biologic-based therapies. In addition to producing clinically-equivalent outcomes to their reference products, studies show biosimilars will contribute to lowering the overall cost of healthcare.
To help Pharmacy & Therapeutics (P&T) committees determine whether biosimilars are appropriate for their health system’s formulary, pharmacy leaders will need to help address three current barriers to adoption: physician support, operational concerns and potential economic considerations.
To read the full article, as originally published in Becker's Hospital Review, click here.